Literature DB >> 26500110

Aberrant miR-21 and miR-200b expression and its pro-fibrotic potential in hypertrophic scars.

Renpeng Zhou1, Qi Zhang2, Yun Zhang3, Shibo Fu1, Chen Wang4.   

Abstract

The post-traumatic hypertrophic scar (HS) is a fibrotic disease with excessive extracellular matrix (ECM) production by fibroblasts in response to tissue injury. Although dysregulation of miRNAs is known to be involved in a variety of pathophysiologic processes, the role of miRNA in hypertrophic scar formation is unclear. Abnormal expression of miRNA in fibrosis has been investigated in several studies. The transforming growth factor β1 (TGF-β1) promotes fibroblasts proliferation, the synthesis of collagen and other extracellular matrix, and ultimately leads to the formation of the HS by inducing excessive deposition of ECM. We identified two miRNAs whose expression was correlated with fibrotic diseases: miR-21 and miR-200b. This study further confirmed that after stimulation with TGF-β1, the expression of miR-21 was increased, whereas the mRNA level of SMAD7 was decreased in fibroblasts. TGF-β1 reduced the expression of miR-200b, while it augmented that of Zinc finger E-box-binding homeobox 1(Zeb1). Our experiments demonstrated that the expression of miR-21 and miR-200b are related to a disorder, and the TGF-β/miR-21/Smad7 and TGF-β/miR200b/Zeb1 pathways might participate in the pathogenesis of HS. Thus, a novel, beyond the traditional methods, approach for HS treatment via miRNA therapeutics could have been provided.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fibrosis; Hypertrophic scar; TGF -β1; miR-200b; miR-21

Mesh:

Substances:

Year:  2015        PMID: 26500110     DOI: 10.1016/j.yexcr.2015.10.018

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  17 in total

1.  Role of the microRNA-29 family in fibrotic skin diseases.

Authors:  Duygu Harmanci; Erdogan Pekcan Erkan; Ayse Kocak; Gul Guner Akdogan
Journal:  Biomed Rep       Date:  2017-05-03

Review 2.  MicroRNA-21 in Skin Fibrosis: Potential for Diagnosis and Treatment.

Authors:  Yan Li; Juan Zhang; Yuying Lei; Lechun Lyu; Ruiling Zuo; Ting Chen
Journal:  Mol Diagn Ther       Date:  2017-12       Impact factor: 4.074

3.  MicroRNA-192 regulates hypertrophic scar fibrosis by targeting SIP1.

Authors:  Yan Li; Julei Zhang; Wei Zhang; Yang Liu; Yuehua Li; Kejia Wang; Yijie Zhang; Chen Yang; Xiaoqiang Li; Jihong Shi; Linlin Su; Dahai Hu
Journal:  J Mol Histol       Date:  2017-09-07       Impact factor: 2.611

Review 4.  Biological approaches for hypertrophic scars.

Authors:  Zhong Lingzhi; Li Meirong; Fu Xiaobing
Journal:  Int Wound J       Date:  2019-12-20       Impact factor: 3.315

5.  MicroRNA-143-3p inhibits hyperplastic scar formation by targeting connective tissue growth factor CTGF/CCN2 via the Akt/mTOR pathway.

Authors:  Shengzhi Mu; Bei Kang; Weihui Zeng; Yaowen Sun; Fan Yang
Journal:  Mol Cell Biochem       Date:  2016-04-13       Impact factor: 3.396

6.  MiR-210-5p regulates STAT3 activation by targeting STAT5A in the differentiation of dermal fibroblasts.

Authors:  Shuyi Wei; Ye Qiu
Journal:  3 Biotech       Date:  2021-04-29       Impact factor: 2.406

Review 7.  Epithelial-to-mesenchymal transition transcription factors in cancer-associated fibroblasts.

Authors:  Josep Baulida
Journal:  Mol Oncol       Date:  2017-06-13       Impact factor: 6.603

Review 8.  Non-Coding RNAs: New Players in Skin Wound Healing.

Authors:  Eva K Herter; Ning Xu Landén
Journal:  Adv Wound Care (New Rochelle)       Date:  2017-03-01       Impact factor: 4.730

9.  MicroRNA-26a inhibits hyperplastic scar formation by targeting Smad2.

Authors:  Jun Qi; Yifei Liu; Kesu Hu; Yi Zhang; Yangyang Wu; Xia Zhang
Journal:  Exp Ther Med       Date:  2018-03-21       Impact factor: 2.447

10.  Aberrantly expressed long noncoding RNAs in hypertrophic scar fibroblasts in vitro: A microarray study.

Authors:  Longxiang Tu; Qi Huang; Shangfeng Fu; Dewu Liu
Journal:  Int J Mol Med       Date:  2018-01-26       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.